Sifting through countless of stocks in the Life Sciences Tools & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Bio-Rad Laboratories, Inc. or Stevanato Group S.p.A. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A. compare based on key financial metrics to determine which better meets your investment needs.

About Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Latest Life Sciences Tools & Services and Bio-Rad Laboratories, Inc., Stevanato Group S.p.A. Stock News

As of September 11, 2026, Bio-Rad Laboratories, Inc. had a $9.9 billion market capitalization, compared to the Life Sciences Tools & Services median of $3.6 million. Bio-Rad Laboratories, Inc.’s stock is up 21.9% in 2026, down 4.8% in the previous five trading days and up 33.37% in the past year.

Currently, Bio-Rad Laboratories, Inc.’s price-earnings ratio is 44.7. Bio-Rad Laboratories, Inc.’s trailing 12-month revenue is $2.6 billion with a 8.6% net profit margin. Year-over-year quarterly sales growth most recently was -0.1%. Analysts expect adjusted earnings to reach $9.483 per share for the current fiscal year. Bio-Rad Laboratories, Inc. does not currently pay a dividend.

As of September 11, 2026, Stevanato Group S.p.A. had a $5.7 billion market cap, putting it in the 69th percentile of all stocks. Stevanato Group S.p.A.’s stock is up 3.9% in 2026, up 1.8% in the previous five trading days and down 19.12% in the past year.

Currently, Stevanato Group S.p.A.’s price-earnings ratio is 37.3. Stevanato Group S.p.A.’s trailing 12-month revenue is $1.4 billion with a 11.0% net profit margin. Year-over-year quarterly sales growth most recently was 4.9%. Analysts expect adjusted earnings to reach $0.705 per share for the current fiscal year. Stevanato Group S.p.A. currently has a 0.3% dividend yield.

How We Compare Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A. Stock Value Grades

Company	Ticker	Value
Bio-Rad Laboratories, Inc.	BIO	D
Stevanato Group S.p.A.	STVN	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Bio-Rad Laboratories, Inc. has a Value Score of 31, which is Expensive. Stevanato Group S.p.A. has a Value Score of 24, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Bio-Rad Laboratories, Inc. or Stevanato Group S.p.A. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Bio-Rad Laboratories, Inc. or Stevanato Group S.p.A. is the better investment when it comes to value.

Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A.’s Quality Grades

Company	Ticker	Quality
Bio-Rad Laboratories, Inc.	BIO	B
Stevanato Group S.p.A.	STVN	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Bio-Rad Laboratories, Inc. has a Quality Score of 66, which is Strong. Stevanato Group S.p.A. has a Quality Score of 75, which is Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A. have a grade of B. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Bio-Rad Laboratories, Inc.	BIO	C
Stevanato Group S.p.A.	STVN	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Bio-Rad Laboratories, Inc. has a Earnings Estimate Score of 48, which is Neutral. Stevanato Group S.p.A. has a Earnings Estimate Score of 57, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Bio-Rad Laboratories, Inc. or Stevanato Group S.p.A. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Bio-Rad Laboratories, Inc. or Stevanato Group S.p.A. is the better investment when it comes to estimate revisions.

Other Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A. Grades

In addition to Quality, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Bio-Rad Laboratories, Inc. or Stevanato Group S.p.A. Stock?

Overall, Bio-Rad Laboratories, Inc. stock has a Value Score of 31, Estimate Revisions Score of 48 and Quality Score of 66.

Stevanato Group S.p.A. stock has a Value Score of 24, Estimate Revisions Score of 57 and Quality Score of 75.

Comparing Bio-Rad Laboratories, Inc. and Stevanato Group S.p.A.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.